Income Statement Presentation 2023
2022: Oncology portfolio
Full year sales stable as portfolio rejuvenation progresses
HER2 franchise
YoY CER growth
Phesgo (+121%)
•
Kadcyla (+7%) with growth ex-US due to adjuvant BC
HER2 franchise
Herceptin
Perjeta (+5%)
+3%
Kadcyla (+7%)
Tecentriq
+14%
Polivy (+85%)
Hematology
Rituxan
-5%
franchise
Gazyva (+9%)
Avastin
-28%
Alecensa
+15%
Cotellic +
Cotellic (-3%)
-5%
Zelboraf
Rozlytrek
+51%
Tarceva -29%
Gavreto +175%
0.0
2.0
4.0
6.0
8.0
CHFbn
•
Perjeta (+5%) driven by International; decline in EU due to conversion
Phesgo (CHF 740m): 33% conversion in early launch countries*
Tecentriq
.
Growth (+14%) driven by adjuvant NSCLC, 1L HCC and 1L SCLC
Hematology franchise
• Venclexta**: Expanding patient share in 1L AML & 1L / R/R CLL
.
Gazyva (+9%): Growth driven by 1L FL and in 1L CLL
Polivy (+85%): Strong 1L DLBCL uptake in early launch countries;
Roche
•
•
NCCN guideline inclusion as category 1 granted in Q1 2023
Lunsumio: EU launch in 3L+ FL ongoing; US approval granted in Dec****
NCCN guideline inclusion as category 2A granted in Q1 2023
Alecensa
•
•
Strong growth (+15%) and 1L ALK+ NSCLC leadership in major markets
Ph III (ALINA) in adjuvant ALK+ NSCLC expected in 2023
2022 Oncology sales: CHF 20.0bn; CER growth -1%; CER-Constant Exchange Rates; * Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (30 countries); ** Venclexta sales booked by
AbbVie and therefore not included; ***Lunsumio launched in the US in Jan 2023; Polivy in collaboration with Seagen; BC=breast cancer; HCC-hepatocellular carcinoma; NSCLC=non-small cell lung cancer; SCLC-small cell lung cancer; AML=acute myeloid
leukemia; R/R CLL-relapsed/refractory chronic lymphocytic leukemia; FL-follicular lymphoma; DLBCL-diffuse large B cell lymphoma; NCCN=national comprehensive cancer network; ALK-anaplastic lymphoma kinase
23View entire presentation